Edition:
India

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

1.86USD
17 Nov 2017
Change (% chg)

$0.16 (+9.41%)
Prev Close
$1.70
Open
$1.72
Day's High
$1.94
Day's Low
$1.72
Volume
20,916
Avg. Vol
23,829
52-wk High
$16.65
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics Q3 loss per share $0.56
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Tuesday, 6 Sep 2016 

Proteostasis Therapeutics Inc :Files to say it is offering 4.3 million shares of its common stock.  Full Article

Proteostasis Therapeutics files for common stock offering
Friday, 26 Aug 2016 

Proteostasis Therapeutics Inc : Files for common stock offering of up to $60 million - SEC filing Source: (http://bit.ly/2bDxfUB) Further company coverage: [PTI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

Proteostasis Therapeutics says appointment of James M. Detore as CFO
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Says appointment of James M. Detore as Chief Financial Officer .Detore joins company from Bluebird Bio, Inc.  Full Article

Proteostasis Therapeutics, Inc. Announces Closing of Initial Public Offering
Thursday, 18 Feb 2016 

Proteostasis Therapeutics, Inc:Says closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share.All of the shares sold in the offering were offered by Proteostasis Therapeutics, Inc.The company's shares began trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol "PTI.".The gross proceeds from the offering are $50.0 million, before deducting underwriting discounts and commissions and expenses associated with the offering payable by the company.Leerink Partners and RBC Capital Markets acted as joint book-running managers.Baird and H.C. Wainwright & Co. acted as co-managers.  Full Article

BRIEF-Proteostasis Therapeutics Q3 loss per share $0.56

* Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update